Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Rating of “Hold” from Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have received an average recommendation of “Hold” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $58.00.

A number of equities research analysts have commented on PSTV shares. D. Boral Capital reissued a “hold” rating on shares of Plus Therapeutics in a report on Tuesday, March 31st. Wall Street Zen raised Plus Therapeutics to a “sell” rating in a report on Saturday, April 4th. Lake Street Capital started coverage on Plus Therapeutics in a report on Tuesday, February 3rd. They issued a “buy” rating and a $50.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a report on Tuesday, April 21st. Finally, Ascendiant Capital Markets reduced their target price on Plus Therapeutics from $475.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, April 9th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in shares of Plus Therapeutics during the second quarter valued at $41,000. Susquehanna International Group LLP acquired a new stake in Plus Therapeutics in the 3rd quarter worth about $46,000. Scientech Research LLC acquired a new stake in Plus Therapeutics in the 3rd quarter worth about $100,000. XTX Topco Ltd acquired a new stake in Plus Therapeutics in the 4th quarter worth about $127,000. Finally, State Street Corp boosted its stake in Plus Therapeutics by 37.1% in the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after buying an additional 127,000 shares during the last quarter. Hedge funds and other institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Stock Performance

Plus Therapeutics stock opened at $6.60 on Wednesday. Plus Therapeutics has a one year low of $2.90 and a one year high of $23.42. The business has a fifty day moving average of $5.71 and a two-hundred day moving average of $9.03. The company has a market cap of $45.43 million, a P/E ratio of -2.87 and a beta of 1.40.

Plus Therapeutics (NASDAQ:PSTV) last released its earnings results on Friday, May 15th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. The business had revenue of $1.03 million during the quarter, compared to analyst estimates of $0.97 million. Sell-side analysts predict that Plus Therapeutics will post -3.66 EPS for the current year.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.